RUZZA, Chiara
 Distribuzione geografica
Continente #
NA - Nord America 3.067
EU - Europa 717
AS - Asia 320
SA - Sud America 8
Continente sconosciuto - Info sul continente non disponibili 2
Totale 4.114
Nazione #
US - Stati Uniti d'America 3.064
CN - Cina 219
IT - Italia 200
PL - Polonia 154
UA - Ucraina 113
TR - Turchia 83
DE - Germania 79
GB - Regno Unito 74
SE - Svezia 36
FI - Finlandia 30
BE - Belgio 14
BR - Brasile 6
IN - India 6
RU - Federazione Russa 6
CA - Canada 3
FR - Francia 3
A2 - ???statistics.table.value.countryCode.A2??? 2
DK - Danimarca 2
HK - Hong Kong 2
JP - Giappone 2
RO - Romania 2
VN - Vietnam 2
BD - Bangladesh 1
BG - Bulgaria 1
CL - Cile 1
ES - Italia 1
IR - Iran 1
KR - Corea 1
KW - Kuwait 1
MY - Malesia 1
NL - Olanda 1
NO - Norvegia 1
PE - Perù 1
PH - Filippine 1
Totale 4.114
Città #
Fairfield 498
Woodbridge 401
Ashburn 283
Houston 224
Seattle 211
Cambridge 194
Ann Arbor 183
Wilmington 183
Chandler 161
Warsaw 154
Jacksonville 152
Ferrara 117
Princeton 57
Beijing 54
Izmir 53
Nanjing 44
Shanghai 44
Milan 38
New York 36
San Diego 32
Dearborn 31
Boardman 24
Addison 15
Brussels 14
Nanchang 14
Shenyang 13
Falls Church 12
Norwalk 11
Bremen 9
Los Angeles 9
London 8
Redwood City 8
Washington 8
Changsha 7
Hebei 7
Ferrara di Monte Baldo 6
Jiaxing 6
Mountain View 6
Auburn Hills 5
Bologna 5
San Mateo 5
Tappahannock 5
Cagliari 4
Helsinki 4
Jena 4
Ningbo 4
Orange 4
Padova 4
Tianjin 4
Augusta 3
Bari 3
Grassano 3
Hounslow 3
Islington 3
Lanzhou 3
Redmond 3
Zhengzhou 3
Bucharest 2
Dong Ket 2
Fort Huachuca 2
Guangzhou 2
Haikou 2
Hefei 2
Hong Kong 2
Indiana 2
Jinan 2
Juiz De Fora 2
La Canada Flintridge 2
Leawood 2
Monmouth Junction 2
Munich 2
Philadelphia 2
Prescot 2
Pune 2
Torino 2
Toronto 2
Walnut 2
Aberdeen 1
Amsterdam 1
Ardabil 1
Belo Horizonte 1
Bonn 1
Boston 1
Changchun 1
Chicago 1
Chiswick 1
Davao City 1
Des Moines 1
Dhaka 1
Falkenstein 1
Fuzhou 1
George Town 1
Granarolo 1
Jesi 1
Kilburn 1
Krasnodar 1
Kunming 1
Kuwait City 1
Köln 1
Lima 1
Totale 3.462
Nome #
Pharmacological and neurobiological studies on Neuropeptide S and its receptor 180
Neuropeptide S reduces mouse aggressiveness in the resident/intruder test through selective activation of the neuropeptide S receptor 144
Behavioural phenotypic characterization of CD-1 mice lacking the neuropeptide S receptor 130
Beta-arrestin 2 rather than G protein efficacy determines the anxiolytic- versus antidepressant-like effects of nociceptin/orphanin FQ receptor ligands 129
Anxiolytic- and panicolytic-like effects of Neuropeptide S in the mouse elevated T-maze. 127
[D-Pen(p-tBuBzl)5]NPS, a novel ligand for the neuropeptide S receptor: structure activity and pharmacological studies 124
Modulation of the NOP receptor signaling affects resilience to acute stress 122
Synthesis and biological activity of human neuropeptide S analogues modified in position 2 120
Pharmacological studies on the NOP and opioid receptor agonist PWT2-[Dmt(1)]N/OFQ(1-13) 118
[(t)Bu-d-Gly(5)]NPS, a pure and potent antagonist of the neuropeptide S receptor: In vitro and in vivo studies 113
Synthesis and Biological Activity of Human Neuropeptide S Analogues Modified in Position 5: Identification of Potent and Pure Neuropeptide S Receptor Antagonists. 110
null 110
Pharmacological characterization of tachykinin tetrabranched derivatives 107
In vitro and in vivo pharmacological characterization of Pronetupitant, a prodrug of the neurokinin 1 receptor antagonist Netupitant 106
In vitro and in vivo pharmacological characterization of the novel neuropeptide S receptor ligands QA1 and PI1 105
Structure-activity study at positions 3 and 4 of human neuropeptide S. 105
null 105
Neuropeptide S receptor ligands: a patent review (2005-2016) 102
In vitro functional characterization of novel nociceptin/orphanin FQ receptor agonists in recombinant and native preparations 99
Further studies at neuropeptide s position 5: discovery of novel neuropeptide S receptor antagonists. 95
Biased Agonism at Nociceptin/Orphanin FQ Receptors: A Structure Activity Study on N/OFQ(1-13)-NH2 95
Synthesis and separation of the enantiomers of the neuropeptide S receptor antagonist (9R/S)-3-oxo-1,1-diphenyl-tetrahydro-oxazolo[3,4-a]pyrazine-7-carboxylic acid 4-fluoro-benzylamide (SHA 68). 94
Tetrabranched Hetero-Conjugated Peptides as Bifunctional Agonists of the NOP and Mu Opioid Receptors 90
Spinal antinociceptive effects of the novel NOP receptor agonist PWT2-nociceptin/orphanin FQ in mice and monkeys 90
null 87
Peptide welding technology – A simple strategy for generating innovative ligands for G protein coupled receptors 80
In vitro and in vivo pharmacological characterization of nociceptin/orphanin FQ tetrabranched derivatives 80
Antinociceptive action of NOP and opioid receptor agonists in the mouse orofacial formalin test 79
null 77
Pharmacological profile of the neuropeptide S receptor: Dynamic mass redistribution studies 77
NOP agonist action of cebranopadol counteracts its liability to promote physical dependence 75
NOP agonists prevent the antidepressant-like effects of nortriptyline and fluoxetine but not R-ketamine 72
Neuropeptide S is a stimulatory anxiolytic agent: A behavioural study in mice 70
In vitro and in vivo pharmacological characterization of the neuropeptide S receptor antagonist [D-Cys(tBu)5]NPS. 60
Dopamine D1 and D2 receptors mediate neuropeptide S-induced antinociception in the mouse formalin test 59
Synthesis and Pharmacological Evaluation of Hybrids Targeting Opioid and Neurokinin Receptors 57
Nociceptin/orphanin FQ receptor agonists increase aggressiveness in the mouse resident-intruder test 55
NOP Ligands for the Treatment of Anxiety and Mood Disorders 55
null 42
Structure-Activity Relationship Studies on Oxazolo[3,4- a]pyrazine Derivatives Leading to the Discovery of a Novel Neuropeptide S Receptor Antagonist with Potent in Vivo Activity 41
Blockade of nociceptin/orphanin FQ signaling facilitates an active copying strategy due to acute and repeated stressful stimuli in mice 38
Novel Mixed NOP/Opioid Receptor Peptide Agonists 36
Effects of non-peptide nociceptin/orphanin FQ receptor ligands on methylphenidate-induced hyperactivity in mice: Implications for bipolar disorders 35
Blockade of NOP receptor modulates anxiety-related behaviors in mice exposed to inescapable stress 33
Detailed in vitro pharmacological characterization of the clinically viable nociceptin/orphanin FQ peptide receptor antagonist BTRX-246040 33
Pharmacological characterization of cebranopadol a novel analgesic acting as mixed nociceptin/orphanin FQ and opioid receptor agonist 30
The concise guide to pharmacology 2019/20: G protein-coupled receptors 30
Functional Selectivity Does Not Predict Antinociceptive/Locomotor Impairing Potencies of NOP Receptor Agonists 23
In vitro and in vivo pharmacological characterization of a neuropeptide S tetrabranched derivative 22
Pharmacological characterization of naloxegol: In vitro and in vivo studies 21
Biased versus Partial Agonism in the Search for Safer Opioid Analgesics 20
Further studies on the pharmacological profile of the neuropeptide S receptor antagonist SHA 68. 19
Blockade of nociceptin/orphanin FQ receptor signaling reverses LPS-induced depressive-like behavior in mice 18
The concise guide to pharmacology 2021/22: G protein-coupled receptors 16
Pharmacology of Kappa Opioid Receptors: Novel Assays and Ligands 14
Racemic synthesis and solid phase peptide synthesis application of the chimeric valine/leucine derivative 2-amino-3,3,4-trimethyl-pentanoic acid 14
Pharmacology, physiology and genetics of the neuropeptide s system 14
Preclinical effects of cannabidiol in an experimental model of migraine 10
Nociceptin/orphanin FQ receptor system blockade as an innovative strategy for increasing resilience to stress 10
Synthesis, Biological Activity and Molecular Docking of Chimeric Peptides Targeting Opioid and NOP Receptors 9
The NOP antagonist BTRX-246040 increases stress resilience in mice without affecting adult neurogenesis in the hippocampus 7
Lack of Direct Effects of Neurotrophic Factors in an In Vitro Model of Neuroinflammation 4
The concise guide to pharmacology 2017/18: Overview 1
In vitro pharmacological characterization of standard and new lysophosphatidic acid receptor antagonists using dynamic mass redistribution assay 1
Totale 4.244
Categoria #
all - tutte 19.049
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 347
Totale 19.396


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019333 0 0 0 0 0 0 0 0 0 0 149 184
2019/20201.122 137 40 37 143 92 145 141 110 106 89 52 30
2020/2021799 45 87 55 72 49 81 66 78 41 102 74 49
2021/2022524 33 35 28 39 37 38 27 41 24 52 35 135
2022/2023455 58 42 23 48 58 44 39 37 50 5 27 24
2023/2024311 32 47 25 14 26 78 22 39 4 21 3 0
Totale 4.244